Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 2/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18214549 | 0.88 | GLO1 (0.33) | BACE1BACE2GLO1DPP4DPP8 | |
| SCHEMBL18214552 | 0.87 | DPP4 (0.37) | BACE1BACE2GLO1DPP4DPP8 | |
| SCHEMBL18214518 | 0.86 | FOLH1 (0.35) | BACE1BACE2GLO1DPP4DPP8 | |
| SCHEMBL22546322 | 0.86 | DPP4 (0.37) | BACE1BACE2GLO1DPP4DPP8 | |
| SCHEMBL18214555 | 0.84 | BACE1 (0.34) | BACE1BACE2GLO1DPP4DPP8 | |
| SCHEMBL19426373 | 0.83 | TLR2 (0.35) | BACE1BACE2GLO1DPP4DPP8 | |
| SCHEMBL21961692 | 0.81 | FOLH1 (0.32) | BACE1BACE2DPP4DPP8DPP9 | |
| SCHEMBL23802494 | 0.81 | DPP4 (0.39) | BACE1BACE2GLO1DPP4DPP8 | |
| SCHEMBL17197667 | 0.80 | USP2 (0.33) | GLO1 | |
| SCHEMBL17813102 | 0.79 | DPP4 (0.34) | BACE1BACE2GLO1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069340-A1 | ANTIFOLATE CONJUGATES FOR TREATING INFLAMMATION | ENDOCYTE INC (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2016179011-A1 | ANTIFOLATE CONJUGATES FOR TREATING INFLAMMATION | ENDOCYTE, INC. (US) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069340-A1 | ANTIFOLATE CONJUGATES FOR TREATING INFLAMMATION | FOLR1, FOLR2, MSR1 | BACE1 3901/4885BACE2 3289/4885GLO1 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.